59 STROKE RATE VARIATION AND ANTICOAGULATION BENEFIT IN AF FUNDING This work did not receive funding. GJG is supported by a VENI grant from the Netherlands Organisation for Health Research and Development (ZonMw number 016.166.030). POTENTIAL CONFLICTS OF INTEREST FR and GJG report unrestricted institutional grants for performing research in the field of atrial fibrillation from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb/Pfizer Alliance and Daiichi Sankyo. The other authors declare that they have no conflicts of interest. CONTRIBUTORS LJ wrote the first version of the letter. All authors critically reviewed and revised the letter. 4
RkJQdWJsaXNoZXIy MTk4NDMw